Precision BioSciences
Update in progressDTIL (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Precision BioSciences, Inc. is a clinical-stage gene editing company focused on in vivo therapies. Its ARCUS genome editing platform enables DNA insertion, removal, and repair. Lead programs include PBGENE-HBV to eliminate HBV cccDNA and inactivate integrated HBV DNA, PBGENE-DMD (Excision) for Duchenne muscular dystrophy, PBGENE-3243 for mitochondrial diseases, and iECURE-OTC for ornithine transcarbamylase deficiency. It has collaborations with TG Cell Therapy and iECURE. Founded in 2006 and headquartered in Durham, NC.
Company score
- Sentiment
- 0.29
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.22
- Governance
- 0.14
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.10
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.19
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEOMr. Michael Amoroso
- Founded2006
- Employees67
- Websiteprecisionbiosciences.com
Identifiers
- ISINUS74019P2074
- FIGIBBG008NSBPV3
- CUSIP74019P108
- CIK0001357874